These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 15239486)

  • 1. The importance of aggressive lipid management in patients at risk: evidence from recent clinical trials.
    Ferdinand KC
    Clin Cardiol; 2004 Jun; 27(6 Suppl 3):III12-5. PubMed ID: 15239486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
    Rosenblit PD
    Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid-lowering therapy and the patient with multiple risk factors: what have we learned from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)?
    Sever PS
    Am J Med; 2005 Dec; 118 Suppl 12A():3-9. PubMed ID: 16356801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atorvastatin efficacy in the primary and secondary prevention of cardiovascular events.
    Arca M; Gaspardone A
    Drugs; 2007; 67 Suppl 1():29-42. PubMed ID: 17910519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current lipid management and low cholesterol goal attainment in common daily practice in Spain. The REALITY Study.
    García Ruiz FJ; Marín Ibáñez A; Pérez-Jiménez F; Pintó X; Nocea G; Ahumada C; Alemao E; Yin D;
    Pharmacoeconomics; 2004; 22 Suppl 3():1-12. PubMed ID: 15669149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cholesterol: precursor to many lipid disorders.
    Jones PH
    Am J Manag Care; 2001 Aug; 7(9 Suppl):S289-98. PubMed ID: 11517815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical trials: Evidence and unanswered questions--hyperlipidaemia.
    Deanfield JE
    Cerebrovasc Dis; 2003; 16 Suppl 3():25-32. PubMed ID: 12740553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atorvastatin: its clinical role in cerebrovascular prevention.
    Gaspardone A; Arca M
    Drugs; 2007; 67 Suppl 1():55-62. PubMed ID: 17910521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Managing dyslipidemia in the high-risk patient.
    Stein EA
    Am J Cardiol; 2002 Mar; 89(5A):50C-57C. PubMed ID: 11900720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
    Evans M; Roberts A; Davies S; Rees A
    Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals.
    Pearson TA; Laurora I; Chu H; Kafonek S
    Arch Intern Med; 2000 Feb; 160(4):459-67. PubMed ID: 10695686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.
    Malhotra HS; Goa KL
    Drugs; 2001; 61(12):1835-81. PubMed ID: 11693468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Declaring war on undertreatment: rationale for an aggressive approach to lowering cholesterol.
    van Dam M; van Wissen S; Kastelein JJ
    J Cardiovasc Risk; 2002 Apr; 9(2):89-95. PubMed ID: 12006916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statins and LDL-cholesterol lowering: an overview.
    Stroes E
    Curr Med Res Opin; 2005; 21 Suppl 6():S9-16. PubMed ID: 16138936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regression of coronary atherosclerosis: an achievable goal? Review of results from recent clinical trials.
    Waters D; Lespérance J
    Am J Med; 1991 Jul; 91(1B):10S-17S. PubMed ID: 1867231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).
    Sever PS; Poulter NR; Dahlöf B; Wedel H; Collins R; Beevers G; Caulfield M; Kjeldsen SE; Kristinsson A; McInnes GT; Mehlsen J; Nieminen M; O'Brien E; Ostergren J
    Diabetes Care; 2005 May; 28(5):1151-7. PubMed ID: 15855581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Best practice--ongoing polemics.
    Paoletti R; Bellosta S
    Atherosclerosis; 1999 May; 143 Suppl 1():S3-6. PubMed ID: 10382831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug treatment of hyperlipidemia in women.
    Walsh JM; Pignone M
    JAMA; 2004 May; 291(18):2243-52. PubMed ID: 15138247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale for treatment.
    Gotto AM
    Am J Med; 1991 Jul; 91(1B):31S-36S. PubMed ID: 1867234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholesterol lowering in diabetes. New evidence supports aggressive LDL-C targets.
    Rosenson RS
    Postgrad Med; 2005 Apr; 117(4):17-20, 23-7. PubMed ID: 15842129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.